Relevant in the context of idiopathic pulmonary fibrosis, DMF-loaded ROS-responsive liposomes (containing DMF 0.5, 2, or 5 mg/kg) administered by inhalation attenuated lung fibrosis in animals through Nrf2 pathway upregulation (Liu C et al., 2022; Liu J et al., 2022); such a promising beneficial profile in a preclinical study clearly opens a new perspective for the DMF use in this clinical condition. The gene discussed is NFE2L2; the disease is pulmonary fibrosis.